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Abstract
 
Viral protein R (Vpr) encoded by HIV-1 is a facultative inducer of apoptosis. When added to
intact cells or purified mitochondria, micromolar and submicromolar doses of synthetic Vpr
cause a rapid dissipation of the mitochondrial transmembrane potential (
 
DC
 
m
 
), as well as the
mitochondrial release of apoptogenic proteins such as cytochrome 
 
c
 
 or apoptosis inducing fac-
tor. The same structural motifs relevant for cell killing are responsible for the mitochondri-
otoxic effects of Vpr. Both mitochondrial and cytotoxic Vpr effects are prevented by Bcl-2, an
inhibitor of the permeability transition pore complex (PTPC). Coincubation of purified or-
ganelles revealed that nuclear apoptosis is only induced by Vpr when mitochondria are present
yet can be abolished by PTPC inhibitors. Vpr favors the permeabilization of artificial mem-
branes containing the purified PTPC or defined PTPC components such as the adenine nucleo-
tide translocator (ANT) combined with Bax. Again, this effect is prevented by addition of re-
combinant Bcl-2. The Vpr COOH terminus binds purified ANT, as well as a molecular
complex containing ANT and the voltage-dependent anion channel (VDAC), another PTPC
component. Yeast strains lacking ANT or VDAC are less susceptible to Vpr-induced killing than
control cells yet recover Vpr sensitivity when retransfected with yeast ANT or human VDAC.
Hence, Vpr induces apoptosis via a direct effect on the mitochondrial PTPC.
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Introduction
 
AIDS is associated with an enhanced apoptotic decay of
various cell types, in particular lymphocytes, monocytes,
and neurons. The mechanisms of this deregulated cellular
turnover are complex and involve host factors, direct viral
effects, and soluble viral proteins including gp120, Tat,
Nef, and viral protein R (Vpr)
 
1
 
 (1–4). Although none of
these mechanisms or factors, taken on their own, can ex-
plain the AIDS-associated depletion of important cell types,
it appears important to understand their function individu-
ally. The 14-kD protein Vpr is abundant in virions (3, 5)
and is detectable in the sera of HIV-1 carriers, correlating
with the viral load (6). Vpr is likely to be important for
AIDS pathogenesis, and loss-of-function mutations of Vpr
are negatively selected in vivo (7). Vpr interacts with mul-
tiple intracellular targets and has pleiotropic effects on viral
replication, cell cycle, and differentiation (3, 5). In addition,
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Abbreviations used in this paper:
 
 AIF, apoptosis inducing factor; ANT,
adenine nucleotide translocator; Atr, atractyloside; BA, bongkrekic acid;
COX, cytochrome 
 
c
 
 oxidase; CsA, cyclosporin A; PI, propidium iodide;
PTPC, permeability transition pore complex; RT, room temperature;
VDAC, voltage-dependent anion channel; Vpr, viral protein R.
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Vpr Targets Mitochondria to Induce Apoptosis
 
Vpr kills lymphocytes (8), monocytes (9), and neurons (10),
either upon infection with 
 
vpr
 
-positive HIV-1 isolates (8, 9)
or upon extracellular addition of the Vpr protein (10, 11).
Intrigued by the pleiotropic cytotoxic potential of Vpr, we
decided to explore the apoptogenic mode of action of this
HIV-1 accessory protein.
Apoptosis research has recently been boosted by the de-
velopment of cell-free systems in which isolated organelles
(nuclei, mitochondria, cytosol, etc.) are coincubated in vitro
(12–19). This approach has generated evidence that mito-
chondrial intermembrane proteins, including cytochrome 
 
c
 
,
apoptosis inducing factor (AIF), procaspases, and heat shock
proteins, are released during apoptosis and are crucial for
the activation of caspases and DNases (17–23). The mecha-
nism responsible for mitochondrial membrane permeabiliza-
tion has been found to involve proapoptotic members of the
Bcl-2 family (Bax, Bak, Bid, etc.; reference 24–28) and/or
the permeability transition pore complex (PTPC), a polypro-
tein complex organized around the two most abundant pro-
teins of the inner and outer mitochondrial membranes, the
adenine nucleotide translocator (ANT; inner membrane) and
the voltage-dependent anion channel (VDAC; outer mem-
brane). ANT, VDAC, Bcl-2, and Bax physically interact
within the inner–outer membrane contact site (27–30). Cell-
free systems also allow mapping of the site of action of
xenobiotic apoptosis inducers. Schematically, two classes of
inducers can be distinguished. First, a variety of different in-
ducers act directly on mitochondria and/or purified PTPC.
This is true for experimental anticancer agents such as lonid-
amine (31), betulinic acid (32), arsenite (33), and diamide
(34), as well as for toxins such as salicylate (35) and masto-
paran (16). In contrast, the majority of apoptosis inducers
act indirectly on mitochondria, e.g., via triggering of the
ceramide pathway, increases in Ca
 
2
 
1
 
 levels, effects on the
subcellular distribution of proteins from the Bcl-2/Bax fam-
ily, caspase activation, or shifts in redox potentials, which
then affect the PTPC (and perhaps alternative permeabili-
zation mechanisms (16, 24–28, 36–38).
Based on the above premises, we decided to elucidate
the apoptogenic mode of action of Vpr, both in cells and
in cell-free systems. Our results indicate that Vpr can di-
rectly target mitochondrial PTPC and permeabilize mito-
chondrial membranes in cell-free systems. Moreover, Vpr
can act on purified PTPC or PTPC components reconsti-
tuted into synthetic membranes. Cell lacking key proteins
from the PTPC become relatively resistant to the cyto-
toxic effect of Vpr. Thus, Vpr represents a novel type of
viral peptide that can interact with the PTPC to permeabi-
lize mitochondrial membranes and trigger the apoptotic
program.
Figure 1. Proapoptotic effects of Vpr and
Vpr-derived peptides (35). (A) Cytocidal ef-
fects of Vpr on Jurkat cells. After overnight
incubation, plasma membrane permeability
was assessed by PI staining. This experiment
was reproduced five times. (B) Acute mito-
chondrial Vpr effects. Jurkat cells were cul-
tured for 2 h with 0.5 mM Vpr52-96, 1 mM
Vpr1-96, 1 mM Vpr1-51, 10 mM CsA, and/
or 50 mM BA, followed by staining with
DCm-sensitive DiOC6(3) and hydroethi-
dine (HE), which reacts with superoxide an-
ion to the fluorochrome ethidium (Eth). (C)
Structural requirements, caspase indepen-
dence, and Bcl-2–mediated inhibition of
Vpr-mediated killing. Jurkat cells transfected
with the human bcl-2 gene, the neomycin
resistance gene only (Neo), or Neo option-
ally cultured with 50 mM of Z-VAD.fmk
were treated with 2 mM Vpr1-96, 2 mM
Vpr1-51, 1 mM Vpr52-96 (or mutants), 5 mM
Vpr71-96 (or mutants), or 5 mM Vpr83-96,
followed by staining with DCm-sensitive
DiOC6(3) (after 2 h as in B), an annexin
V–FITC conjugate (for the determination of
surface phosphatidylserine exposure, after
12 h of culture), or fixed with ethanol and
stained with PI to determine the frequency
of hypoploid cells (at 12 h). Data are pooled
from five independent experiments, and
each data point has been repeated at least
three times.
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Materials and Methods
 
Vpr Peptides and Constructs.
 
Vpr1-96, Vpr-derived peptides, and
NCp7 where synthetized by automated solid phase synthesis us-
ing the FMOC strategy and purified by reverse-phase HPLC (39,
40). The peptides were analyzed by electrospray mass spectrometry
and found to be 
 
$
 
98% pure. The FLAG-Vpr–expressing vector
was constructed by PCR amplification of p90
 
1
 
, which contains the
whole HIV-1 Lai genome. Both primers, FlVpr (TCCGGATC-
CACCATGGACTACAAAGACGACGATGACAAATCGATG-
GAACAAGCCC [coding sequence of the FLAG-derived epitope
(MDYKDDDDKS) plus sequence 5,141–5,153 of Lai]) and VLCas
(ATTTTCCTATATTCTATGATTACTATGGACC [5,737–
5,707]), resulted in a 638-bp fragment, which was cloned into the
blunted EcoR1–BamH1 sites of the pcDNA3.1 eukaryotic ex-
pression vector (Invitrogen Corp.). This construct was transfected
into COS cells using Lipofectamine (Life Technology).
 
Cells and Apoptosis Modulation.
 
Jurkat-Neo and Jurkat-Bcl-2
clones (reference 41; a gift from Dr. N. Israel, Pasteur Institute,
Paris, France), and CEM-C7 cells were cultured in RPMI 1640
Glutamax medium supplemented with 10% FCS, antibiotics, and
0.8 
 
m
 
g/ml G418. 2B4.11 mouse T cell hybridoma cell lines sta-
bly transfected with an SFFV.neo vector, containing the human
 
bcl-2
 
 gene or the neomycin (Neo) resistance gene, and COS cells
were cultured in DMEM Glutamax medium supplemented with
Hepes, antibiotics, and 10% FCS.
 
 
 
PBS-washed cells (1–5 
 
3
 
 10
 
5
 
/
ml) were incubated for 30 min with Vpr or Vpr-derived peptides
in isotonic glucose–Hepes buffer (2.4% glucose, 13 mM Hepes,
68 mM NaCl, 1.3 mM KCl, 4 mM Na
 
2
 
HPO
 
4
 
, and 0.7 mM
KH
 
2
 
PO
 
4
 
, pH 7.2), followed by culture in complete culture me-
dium supplemented with cyclosporin A (CsA; 1 
 
m
 
M; Novartis),
bongkrekic acid (BA; 50 
 
m
 
M; gift of Dr. J.A. Duine, Delft Univer-
sity, Delft, The Netherlands), and/or the caspase inhibitor 
 
N
 
-ben-
zyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk; 50
 
m
 
M; Bachem Bioscience, Inc.). During exposure to Vpr or Vpr-
derived peptides, human primary PBLs from healthy donors, pu-
rified with Lymphoprep (Pharmacia), were cultured in RPMI
1640 Glutamax medium without any addition of serum. In con-
trast, PHA blasts (24 h of 1 
 
m
 
g/ml PHA-P [Wellcome Indus-
tries]; 48 h with 100 U/ml human recombinant IL-2 [Boehringer
Mannheim]) were cultured with 10% FCS.
 
Determinations of Apoptosis-associated Alterations in Intact Cells.
 
For
cytofluorometry, the following fluorochromes were employed:
3,3
 
9
 
-dihexyloxacarbocyanine iodide (DiOC
 
(6)
 
3; 40 nM) for mito-
chondrial transmembrane potential (
 
DC
 
m
 
) quantification, hydro-
ethidine (4 
 
m
 
M) for the determination of superoxide anion gen-
eration, and propidium iodide (PI; 5 
 
m
 
M) for the determination
of viability (42). The frequency of subdiploid cells was deter-
mined by PI (50 
 
m
 
g/ml) staining of ethanol-permeabilized cells
treated with 500 
 
m
 
g/ml RNase (Sigma Chemical Co.; 30 min,
room temperature [RT]) in PBS, pH 7.4, supplemented with 5 mM
glucose (43). For in situ determinations, cells were fixed with 4%
paraformaldehyde and 0.19% picric acid in PBS, pH 7.4, for 1 h
at RT. Fixed cells were permeabilized with 0.1% SDS in PBS at
RT for 5 min, blocked with 10% FCS, and stained with an mAb
specific for native cytochrome 
 
c 
 
(mAb 6H2.B4 [PharMingen], re-
vealed by a goat anti–mouse IgG1 PE conjugate [Southern Biotech-
nology Associates, Inc.]), Hsp60 (mAb H4149 [Sigma Chemical
Co.], revealed by a goat anti–mouse IgG1 FITC conjugate), cyto-
chrome 
 
c
 
 oxidase (COX; mAb 20E8-C12 [Molecular Probes,
Inc.], revealed by a goat anti–mouse IgG2a FITC conjugate), or a
rabbit antiserum generated against amino acids 151–200 of AIF
([reference 19]; revealed with a goat anti–rabbit IgG conjugated
Figure 2. Effects of Vpr on human primary PBLs. (A) Effect of Vpr
and Vpr-derived peptides on PBLs. Cells were cultured for 2 h in the
presence of 2 mM Vpr, Vpr1-52, Vpr52-96, Vpr52-96R73A, and/or 50
mM BA, followed by staining with PI (for the determination of plasma
membrane permeability) and the DCm-sensitive dye DiOC6(3). (B)
Dose–response curve for different Vpr-derived peptides. Results are rep-
resentative of three independent experiments.
 
to PE [Southern Biotechnology Associates, Inc.]). Alternatively,
unfixed cells were incubated with the 
 
DC
 
m
 
-sensitive dyes chlo-
romethyl-X-rosamine (CMXRos; 50 nM; Molecular Probes, Inc.)
or 5,5
 
9
 
,6,6
 
9
 
-tetrachloro-1,1
 
9
 
,3,3
 
9
 
-tetraethylbenzimidazolcarbocy-
anine iodide (JC-1; 1 
 
m
 
M; Molecular Probes, Inc.), the 
 
DC
 
m
 
-insen-
sitive dye Mitotracker green (1 
 
m
 
M; Molecular Probes, Inc.),
and/or Hoechst 33342 (2 
 
m
 
M; Sigma Chemical Co.) (27). Confo-
cal microscopy was performed on a Leica TC-SP (Leica Microsys-
tems) equipped with an ArKr laser mounted on an inverted Leica
DM IFBE microscope with a 63 
 
3
 
 1.32 NA oil objective.
 
Preparation of Organelles, Cell-free Systems of Apoptosis, and As-
sessment of Mitochondrial Parameters.
 
Mitochondria were purified
from rat liver (36) and resuspended in 250 mM sucrose plus 0.1
mM EGTA plus 10 mM 
 
N
 
-tris(hydroxymethyl)methyl-2-amino-
ethanesulfonic acid, pH
 
 
 
7.4. Cytosols from control or 
 
a
 
CD95-
treated (CH-11; 500 ng/ml; 2 h; Immunotech) cells (10
 
7
 
 cells/
100 
 
m
 
l in cell-free system buffer [reference 37]) were prepared by
five freeze–thaw cycles in liquid nitrogen, followed by centrifu-
gation (1.5 
 
3
 
 10
 
5
 
 
 
g
 
, 4
 
8
 
C, 1 h) as described (37). HeLa cell nuclei
(10
 
3
 
 nuclei per microliter) were incubated (60 min at 37°C) in the
presence (or not) of isolated mitochondria, mitochondrial superna-
tants, cytosols from CEM-C7 cells, or recombinant AIF (19), and/
or Vpr peptides. Then, nuclei were stained with PI (10 
 
m
 
g/ml;
Sigma Chemical Co.), followed by cytofluorometric determina-
tion of the frequency of hypoploid nuclei (37). To determine large
amplitude swelling, mitochondria (0.5 mg protein per milliliter)
were resuspended in Swelling buffer (200 mM sucrose, 10 mM Tris-
MOPS (3-[
 
N
 
-morpholino]-propanesulfonic acid), pH 7.4, 5 mM
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Tris-succinate, 1 mM Tris-phosphate, 2 
 
m
 
M rotenone, and 10 
 
m
 
M
EGTA-Tris) and monitored in an F5400 fluorescence spectrometer
(Hitachi) for 90° light scattering (545 nm) after addition of 1 mM
atractyloside (Atr; Sigma Chemical Co.), 1 
 
m
 
M CsA, 50 
 
m
 
M BA,
and/or Vpr peptides. For determination of 
 
DC
 
m
 
, mitochondria
(0.5 mg protein per milliliter) were incubated in swelling buffer
supplemented with 1 
 
m
 
M rhodamine 123 (Rh123; Molecular
Probes, Inc.), and the dequenching of Rh123 fluorescence (exci-
tation 505 nm, emission 525 nm) was measured (44). Superna-
tants from mitochondria (6,800 
 
g for 15 min, then 20,000 g for 1 h;
4°C) were frozen at 2808C until determination of AIF activity or
immunodetection of cytochrome c (mouse mAb clone 7H8.2C12;
PharMingen) and AIF (rabbit polyclonal antiserum; reference 19).
Caspase activity in the mitochondrial supernatant was measured
using Ac-DEVD-amido-4-trifluoromethylcoumarin (Bachem Bio-
science, Inc.) as fluorogenic substrate (18).
Binding Assays and Immunoblots. Isolated rat liver mitochondria
(250 mg of protein in 100 ml of swelling buffer) were incubated for
30 min at RT with 5 mM Vpr52-96 or biotin–Vpr52-96. The
washed mitochondrial pellet (104 g, 10 min, 4°C; two washes) was
then lysed with 150 ml of a buffer containing 20 mM Tris/HCl, pH
7.6, 400 mM NaCl, 50 mM KCl, 1 mM EDTA, 0.2 mM PMSF,
aprotinin (100 U/ml), 1% Triton X-100, and 20% glycerol. Such
extracts were diluted with two volumes of PBS plus 1 mM EDTA
before the addition of 150 ml avidin–agarose (ImmunoPure; Pierce
Chemical Co.) to capture the biotin-labeled Vpr52-96 complexed
with its mitochondrial ligand(s) (2 h at 4°C in a roller drum). The
avidin–agarose was washed batchwise with PBS (five times, 5 ml;
1,000 g, 5 min, 4°C), resuspended in 100 ml of twofold-concen-
trated Laemmli buffer containing 4% SDS and 5 mM b-ME, incu-
bated for 10 min at RT, and centrifuged (1,000 g, 10 min, 4°C). Fi-
nally, the supernatants were heated at 95°C for 5 min and analyzed
by SDS-PAGE (12%), followed by silver staining (BioRad kit) or
Western blot and immunodetection of VDAC (antiporin 31HL
mAb; Calbiochem Corp.), subunit IV of COX (mAb from Molec-
ular Probes, Inc.), and a rabbit polyclonal antiserum against human
ANT (provided by Dr. H.H. Schmid, The Hormel Institute, Uni-
versity of Minnesota, Austin, MN; reference 45). In one series of
experiments, PBL-derived PHA lymphoblasts were cultured in the
presence of 1 mM biotin–Vpr52-96, followed by fixation/perme-
abilization (4% paraformaldehyde, 0.19% picric acid in PBS, pH
7.4, for 1 h at RT) and staining with a streptavidin–PE conjugate
(Sigma Chemical Co.). For surface plasmon resonance measure-
ments, upgraded Biacore 1000 equipment (Pharmacia) was used.
0.8 ng/mm2 biotin–Vpr52-96 was absorbed to streptavidin co-
valently linked to a CMb chip according to the standard procedure.
Three dilutions (35, 70, and 140 nM) of ANT (purified to $95%,
as described above) were passed at a flux of 5 ml/min for 10 min,
and data were calculated using BIAeval.3 software (Pharmacia).
Purification and Reconstitution of PTPC, ANT, and Bcl-2/Bax
Proteins in Liposomes. PTPC from rat brain or ANT from rat heart
was purified and reconstituted into liposomes via detergent dialy-
sis following published protocols (27, 29). Recombinant human
Bcl-2 (1-218) or mouse Bax (1-171), both lacking the hydropho-
bic transmembrane domain and produced and purified as described
(25, 27, 29), were added during the dialysis step. Liposomes re-
covered from dialysis were ultrasonicated, charged on Sephadex
G75 or G25 columns (Pharmacia) for PTPC or ANT, respec-
Figure 3. Mitochondrial Vpr
effects in intact cells. COS cells
were treated for 3 h with 1 mM
Vpr1-51 (negative control) or
Vpr52-96, fixed, permeabilized,
and immunostained with anti-
bodies specific for AIF or cyto-
chrome (Cyt.) c (both normally
in the mitochondrial intermem-
brane space revealed PE, red flu-
orescence) and the mitochon-
drial matrix protein Hsp60 or the
inner mitochondrial membrane
protein COX (both revealed by
FITC, green fluorescence). In
addition, cells were stained with
the DCm-sensitive dye CMXRos
(red fluorescence) and the DNA
intercalating agent Hoechst 33342
(blue fluorescence). The histo-
grams indicate the percentage of
cells manifesting mitochondrio-
nuclear AIF translocation, mito-
chondriocytosolic cytochrome c
translocation, or a low DCm after
treatment with different Vpr pep-
tides (1 mM) in the presence or
absence of Z-VAD.fmk (50 mM).
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tively, and eluted with 125 mM sucrose plus 10 mM Hepes, pH
7.4. Aliquots (z107) of liposomes were incubated during 30 min
at RT in 125 mM sucrose plus 10 mM Hepes, pH 7.4, in the
presence or absence of the indicated Vpr peptides, CsA (1 mM),
BA (50 mM), or Atr (50 mM). Then, liposomes were equilibrated
with DiOC6(3) (80 nM, 20–30 min at RT; Molecular Probes,
Inc.) and analyzed in a FACSVantage™ cytofluorometer (Becton
Dickinson) for DiOC6(3) retention as described (27, 29). Triplicates
of 5 3 104 liposomes were analyzed, and results were expressed as
percent reduction of DiOC6(3) fluorescence, considering the re-
duction obtained with 0.02% SDS (15 min, RT) as the 100% value.
Yeast Strains and Clonogenic Assays. M3 wild-type Saccharo-
myces cerevisiae (genotype: MATa lys2 his4 trp1 ade2 leu2 ura3
Canr); VDACD1 (genotype like M3, but VDAC1::LEU2),
VDACD1D2 (genotype like M3, VDAC1::LEU2, VDAC2::
TRP1); VDACD1,2high (genotype like VDACD1, but overexpressing
VDAC2 as a multicopy suppressor of low growth phenotype; ref-
erence 46); VDACD1/hVDAC1 (genotype like VDACD1, retrans-
fected with human VDAC; reference 47; gift from Dr. M. Forte,
Vollum Institute, Portland, OR). The S. cerevisiae W301-1B control
strain (MATa, ade2, leu2, his3, trp1, ura3), ANTD1D2 (genotype
like W301-1B, but LEU2::aac1, HIS3::aac2; reference 48; gift from
T. Drgon, National Institutes of Health, Bethesda, MD) and
ANTD1D2 retransfected with the yeast ANT2 gene (reference 49;
gift from Dr. M. Klingenberg, University of Munich, Germany)
(47, 48) were treated with Vpr-derived peptides (1 h in H2O) as de-
scribed (50), followed by plating on standard YPD agarose and
quantification of the percentage of surviving clones after 48 h of
culture. In addition, PTY44 wild-type yeast cells (genotype: MATa
leu2-3, 112; lys2, trp1-D1, ura3-52) and yme1-D1 (genotype like
PTY44, but yme1-D1::URA3, TRP1; gift from K.H. White, Uni-
versity of Wyoming, Laramie, WY; reference 51) were cultured
in supplemented DOB medium (Bio 101).
Results and Discussion
Structural Motifs Required for the Cytotoxic Effects of Vpr on
Intact Cells. Synthetic Vpr protein (96 amino acids) kills Jur-
kat lymphoma cells (Fig. 1 A) as well as a variety of other cell
lines (references 10 and 11; data not shown). This effect was
mimicked by the COOH-terminal moiety of the molecule
Vpr52-96 but not by its NH2-terminal moiety (Vpr1-51; Fig.
1 A). As described for other models of apoptosis (38), Vpr (or
Vpr52-96, not Vpr1-51) induced an early loss of DCm, as de-
tected by the potential-sensitive fluorochrome DiOC6(3) (Fig.
1 B). Abolition of Vpr52-96 homodimerization by replace-
ment of two leucine residues by alanines (L60A L67A; refer-
ence 40) did not affect its apoptogenic function. In contrast,
Figure 4. Effects of Vpr on a cell-free sys-
tem of apoptosis. (A) Determination of the sub-
cellular target of Vpr in a cell-free system of
nuclear apoptosis. Nuclei purified from HeLa
cells were incubated for 60 min with the indi-
cated combinations of Vpr alone (1 mM), cyto-
sol (Cyto.; obtained from CEM cells/10 mg
protein per milliliter), mitochondria (Mito.;
purified from mouse liver; 0.5 mg mitochon-
drial protein per milliliter), recombinant mouse
AIF1-612 (100 mg/ml), cytosol from Fas-
treated CEM cells (10 mg protein per millili-
ter), or Atr (1 mM), followed by PI staining
and DNA content analysis of nuclei (16). (B)
Structural requirements and CsA-mediated in-
hibition of Vpr-induced release of mitochon-
drial apoptogenic factors. Mitochondria were
treated for 30 min with 1 mM of Vpr or Vpr-
derived peptides, 1 mM CsA, and/or 1 mM
Atr. The supernatants of these mitochondria
were added to purified nuclei for a period of
60 min, followed by PI staining and determi-
nation of the frequency of hypoploid nuclei.
Alternatively, Vpr-derived peptides were added
directly to nuclei. (C) Vpr-induced mitochon-
drial release of potentially apoptogenic pro-
teins. Mitochondrial supernatants treated as in
B were subjected to immunoblot detection of
cytochrome (Cyt.) c or AIF. Alternatively, the
capacity of supernatants to cleave the fluoro-
genic caspases substrate DEVD.afc was assessed.
(D) Bcl-2–mediated inhibition of nuclear apop-
tosis induced in the cell-free system. Mito-
chondria (M.) were purified from 2B4.11 T cell
hybridoma cells expressing a Neo control vec-
tor or human Bcl-2. These organelles were left
untreated (Co.), subjected to lysis, or treated
with 1 mM of the indicated Vpr-derived pep-
tide, followed by recovery of the supernatant
and determination of its apoptogenic effects on
isolated HeLa nuclei as in A.
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replacement of arginine (R) residues situated within or be-
tween the two functionally important H(S/F)RIG motifs (52)
(R73A or R77A or R80A) greatly reduced the apoptogenic
effect of Vpr52-96. A peptide containing this motif (Vpr71-
96, but not Vpr71-96 R73A R80A) was sufficient to induce
apoptosis (Fig. 1 C). Systematic dose–response studies re-
vealed a significant difference in the ED50 of these R-mutated
peptides and their wild-type equivalents (see Fig. 6 A). These
observations correlate with the fact that R80 mutations reduce
cell killing by vesicular stomatitis virus (VSV)-G–pseudotyped
HIV-1 in vitro (8) and that R73 and R80 are extremely con-
served among pathogenic HIV-1 isolates. Agents that interact
with the H(S/F)RIG motifs such as RNA or DNA (53) neu-
tralized the cytocidal effect of Vpr (not shown). A strict
correlation was found between the DCm collapse induced
by different Vpr-derived peptides and apoptosis induction
at the plasma membrane and nuclear levels (Fig. 1 C). Very
similar data have been obtained with several human cell
lines (U937, CEM, HeLa), COS cells, and mouse thymo-
cytes (not shown), as well as human primary PBLs (Fig. 2).
Thus, Vpr or Vpr52-96 (but not Vpr1-51) causes a DCm
dissipation that precedes the loss of viability in human PBLs,
and this effect is reduced when the mutant Vpr52-96 R73A
is employed (Fig. 2).
Mitochondrial Effects of Vpr Added to Intact Cells. In Jur-
kat cells, Vpr caused a loss of DCm, which was followed by
an increase in the production of superoxide anion (Fig. 1 B)
and nuclear apoptosis (Fig. 1 C). This early effect on the
DCm (1–2 h after addition of Vpr or Vpr52-96) was tran-
siently inhibited by CsA and BA, two inhibitors of the
PTPC (Fig. 1 B). Similar results were obtained with primary
cells such as mouse thymocytes (not shown) and human pri-
mary PBLs, in which the DCm reducing effect of Vpr or
Vpr52-96 is counteracted by the ANT ligand BA (Fig. 2 A).
The DCm loss was also inhibited by overexpression of Bcl-2
(Fig. 1 C), an endogenous cytoprotective protein acting on
the PTPC (27, 29). Bcl-2 concomitantly prevented other
Vpr-induced features of apoptosis, such as phosphatidylserine
exposure on the plasma membrane and nuclear DNA loss
(Fig. 1 C). In contrast, the pancaspase inhibitor Z-VAD.fmk
Figure 5. Vpr-induced swelling and DCm dissipation in
isolated mitochondria. Rat liver mitochondria were exposed
to Vpr (2 mM) or the indicated Vpr derivative (1 mM), CsA
(5 mM; added 1 min before Vpr to mitochondria), BA (50
mM; added 1 min before Vpr to mitochondria), a random
eicosadesoxynucleotide (DNA; 1 mM), total cell RNA
(1 mM), or Ncp7 (10 mM; added to Vpr 1 min before joint
addition to mitochondria). Mitochondrial swelling (measured
as 908 light scattering at 545 nm) or the DCm (measured as
Rh123 dequenching) were monitored continuously. DCm
and swelling determinations yielded concordant results. Rep-
resentative curves obtained with either of the two methods
are shown.
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failed to prevent the DCm dissipation, although it did re-
duce the (caspase-dependent) DNA loss resulting in hy-
poploidy (Fig. 1 C). Vpr52-96 induced, in intact cells, the
mitochondrionuclear translocation of AIF and the mito-
chondriocytosolic translocation of cytochrome c, as detected
by confocal immunofluorescence microscopy (Fig. 3). Vpr
also caused nuclear chromatin condensation (measured with
Hoechst 33342), as well as a dissipation of the DCm, as
measured with the DCm-sensitive dye CMXRos (Fig. 3).
Again, Z-VAD.fmk (which did prevent end-stage nuclear
chromatin condensation) had no mitochondrioprotective
effects (Fig. 2). Altogether, these findings indicate that the
mitochondrial effects of Vpr are caspase independent yet
suppressed by PTPC inhibitors such as CsA, BA, or Bcl-2.
Determination of the Subcellular Target Responsible for the Apop-
togenic Vpr Effect in a Cell-free System. Vpr has been sug-
gested to act on different subcellular targets including the
nucleus (5), the plasma membrane (10, 54), and mitochondria
(55). To map the subcellular site of its apoptogenic action,
we added Vpr to purified HeLa nuclei and determined the
minimum requirements for the induction of chromatin
degradation. Vpr alone had no effects on nuclei, nor did it
activate any cytosolic activity resulting in nuclear apoptosis
(Fig. 4 A). In contrast, Vpr did become apoptogenic in the
presence of mitochondria (Fig. 4 A). This suggests that Vpr
acts primarily on mitochondria (rather than on nuclei or
cytosolic proteins) to trigger the induction of apoptosis.
Supernatants of mitochondria treated with Vpr contain a
factor that provokes nuclear apoptosis in the cell-free system
(Fig. 4 B), immunodetectable AIF (which accounts for this
bioactivity; reference 19), immunodetectable cytochrome c,
and a caspase activity cleaving DEVD.afc (Fig. 4 C) (18, 56).
The release of these mitochondrial intermembrane proteins
was induced by the entire Vpr molecule, its COOH-termi-
nal moiety (Vpr52-96 or Vpr71-96), or a short peptide frag-
ment containing the two H(S/F)RIG motifs (Vpr71-82)
(Fig. 4, B and C), but not by Vpr-derived peptides in which
R73 and R80 were mutated (Fig. 4 B). Altogether, the data
obtained in the cell-free system suggest that Vpr can exert
most if not all of its apoptogenic potential by directly com-
promising the barrier function of mitochondrial membranes.
Mechanisms of Vpr Effects on Isolated Mitochondria: Structural
Analysis and Evidence for the Involvement of the PTPC. The
release of mitochondrial proteins induced by Vpr in vitro
was blocked by the PT pore inhibitor CsA (Fig. 4, B and
C). Moreover, mitochondria isolated from Bcl-2–overex-
pressing cells were refractory to the Vpr-induced release of
AIF activity (Fig. 4 D). The fact that some of the Vpr ef-
fects were inhibited by PTPC inhibitors (CsA, BA, or
Bcl-2) suggested that Vpr can act on the mitochondrial PT
pore, the opening of which can be a rate-limiting step of
the apoptotic process. Accordingly, Vpr induced two hall-
marks of PTPC opening when added to purified mito-
chondria, namely mitochondrial volume increase and DCm
dissipation (Fig. 5), and both of these effects were inhibited
by CsA and BA. The effect of free holo Vpr on isolated
mitochondria is fully mimicked by Vpr52-96 but not by
Vpr52-96 R73A, Vpr52-96 R77A, or Vpr52-96 R80A
(Fig. 5). Preincubation of Vpr with a molar excess of RNA
or DNA (which bind to the Vpr71-82 motif; reference 53)
abolished its effects on isolated mitochondria (Fig. 5), cor-
relating with the data obtained in cells (not shown). In con-
trast, synthetic HIV-1 nucleocapsid protein NCp7 (which
binds to the extreme COOH terminus of Vpr; reference
39) does not inhibit Vpr effects on mitochondria (Fig. 5).
Thus, the structural motifs of Vpr responsible for direct, pre-
sumably PTPC-mediated mitochondrial effects in vitro (Fig.
5) and apoptosis induction in intact cells (Fig. 1 C) are the
same. This fact is also underscored by the comparison of
the ED50 of different Vpr peptides determined on intact
cells (Fig. 6 A) and purified mitochondria (Fig. 6 B).
Mitochondrial Localization of Vpr. If Vpr acted on mito-
chondria to induce apoptosis, then at least some Vpr pro-
tein should be found in mitochondria from intact cells. To
determine the subcellular localization of Vpr, epitope-
tagged (FLAG)Vpr was transfected into COS cells and was
revealed by a PE-labeled anti-FLAG antibody (red fluo-
rescence). Simultaneously, mitochondria were stained with
an FITC-conjugated anti-Hsp60 antibody (green fluores-
cence). In accord with previous observations of a punctuate
cytoplasmic localization of Vpr (57, 58), we found that z30%
of Vpr-expressing cells exhibited an exclusively cytoplas-
mic Vpr staining pattern (Fig. 7 A). These cells appear to be
programmed to die (not shown), which may explain why
they represent only a fraction of the entire population. In
such cells, most of the Vpr-dependent red fluorescence colo-
Figure 6. Comparison of the ED50 of different Vpr-derived peptides in
acute cytotoxicity and mitochondrial swelling assays. (A) Half-maximal
effect (ED50) of Vpr-derived peptides on Jurkat cells. Cells were stimulated
for 2 h as in Fig. 1 B, followed by cytofluorimetric determination of the
frequency of DCmlow cells with DiOC6(3). The dose causing DCm dissipa-
tion in 50% of the cells was extrapolated as the ED50. Results (X 6 SD)
were obtained in six independent experiments in which each peptide was
tested at least three times. (B) ED50 of Vpr-derived peptides on purified mi-
tochondria. Different concentrations of Vpr or Vpr-derived peptides were
added to purified mitochondria as in Fig. 5, and the dose yielding an ED50
on mitochondrial swelling (measured as 90° light scattering at 545 nm, 300 s
after addition of the peptide) was extrapolated from the dose–response
curve (log 2 dilutions). Results were obtained in 10 independent experi-
ments, and each peptide was used at least three times.
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calizes with the Hsp60 protein, giving rise to a yellow (red
plus green) staining pattern. Very little Vpr is localized in
the nonmitochondrial compartment (red fluorescence; Fig. 7
A). To confirm this observation in another experimental
system, we added biotinylated Vpr52-96 to human primary
PBLs or to PHA lymphoblasts. Vpr52-96 was then de-
tected by means of a streptavidin–PE conjugate. Cells were
counterstained with Mitotracker green (which labels mito-
chondria independently from their DCm) and Hoechst
33342 (which labels nuclei) to determine the subcellular
distribution of Vpr. After an initial enrichment in the
plasma membrane (not shown), biotinylated Vpr52-96 was
specifically recruited to mitochondria (Fig. 7 B).
Direct Interaction of Vpr with the PTPC via ANT. To iden-
tify the putative mitochondrial receptor of Vpr, purified
mitochondria were incubated with biotinylated Vpr52-96
(which is as efficient as nonmodified Vpr52-96 in inducing
mitochondrial swelling; not shown), followed by purifica-
tion of biotin–Vpr52-96 binding proteins on avidin–agarose.
This led to the selective recovery of very few proteins,
among which we identified VDAC and ANT (but not
COX) by immunoblotting (Fig. 8 A). Neither VDAC nor
ANT was recovered if mitochondria were pretreated with
BA (Fig. 8 B), indicating that BA can compete with
Vpr52-96 for ANT binding and/or that a BA-induced
conformational change abolishes the Vpr–ANT interac-
tion. Surface plasmon resonance (see Materials and Meth-
ods) measurements confirmed that biotinylated Vpr52-96
immobilized to a streptavidin matrix binds to purified (.95%)
ANT with an affinity constant of KA 5 7.4 3 108 M21 (kon 5
1.61 3 106 M21s21; koff 5 2.16 3 1023 s21). These results
suggest that Vpr is recruited to the PTPC via a direct, spe-
cific interaction with ANT.
To confirm the hypothesis that Vpr might permeabilize
mitochondrial membranes by a direct effect on the PTPC,
we purified this molecular complex from brain (27, 29), re-
constituted it into liposomes, and measured the capacity of
Vpr to permeabilize the liposomal membrane (Fig. 9 A).
Vpr or Vpr52-96 increases the permeability of liposomes
containing the PTPC, and this effect is inhibited by CsA or
BA (Fig. 9 A). In addition, Vpr52-96 acts on a combina-
tion of two proteins from the PTPC, ANT plus Bax, and
this effect is suppressed by recombinant Bcl-2 (Fig. 9 B).
Thus, Vpr acts on the PTPC to perturb the barrier function
of mitochondrial membranes.
Genetic Evidence for PTPC-mediated Vpr Cytotoxicity. The
essential components of the PTPC include the two most
abundant proteins of the outer and inner mitochondrial mem-
branes, VDAC and ANT, respectively (27, 29, 30). We there-
fore examined the cytotoxic effect of Vpr52-96 on a series
Figure 7. Subcellular localiza-
tion of Vpr in different cell types.
(A) Subcellular localization of
transfected Vpr. COS cells were
transfected with pcDNA3.1 vec-
tor only or with pcDNA-FLAG-
Vpr expression vector, followed
by immunofluorescence detec-
tion (mouse mAb M2 anti-FLAG;
Sigma Chemical Co.) of the
FLAG (red fluorescence) as well as
of the mitochondrial protein
Hsp60 (green fluorescence) by
confocal microscopy. Fine analysis
of the fluorescence distribution
(right panel) reveals partial colo-
calization of Vpr and Hsp60. The
micrograph of the FLAG-Vpr–
expressing cells represents z30%
of the transfected cells with a pre-
dominantly cytoplasmic staining.
The remaining cells showed either
a predominantly nuclear/perinu-
clear Vpr (z40%) distribution or a
mixed (z20%) phenotype. (B)
Subcellular localization of soluble
Vpr52-96 added to cells. Primary
human PBLs or PHA lympho-
blasts derived from them were in-
cubated in the absence (Co.) or
presence of 1 mM biotin–Vpr52-
96 for 30 min, counterstained
with Mitotracker green (100 nM
during the last 30 min of culture),
fixed, and stained with a streptavi-
din–PE conjugate (red fluorescence) as well as the DNA intercalating dye Hoechst 33324 (blue fluorescence). Note the clear overlap between green and red
fluorescence (yellow), indicating a mitochondrial localization of Vpr52-96 30 min after the addition of the peptide. Aliquots from control cells and biotin–
Vpr52-96–treated cells were stained with the potential-sensitive dye JC-1 (right panel). Control cells exhibited an elevated DCm (red fluorescence), whereas
Vpr52-96–treated cells had a low DCm (green fluorescence). Micrographs are representative for .90% of the cells, and the experiment was performed four times.
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of S. cerevisiae (yeast) strains in which VDAC or ANT had been
invalidated by homologous recombination. Yeast cells ren-
dered deficient for one or two of the principal VDAC isoforms
(VDACD1 or VDACD1D2) or the two principal ANT iso-
forms (ANTD1D2) are more resistant to Vpr52-96 than their
respective wild-type control cells (Fig. 10, A and B). This rela-
tive resistance is abolished by genetic interventions known to
correct the metabolic deficiencies caused by VDAC1 knock-
out (overexpression of VDAC2 or transfection with human
VDAC1; references 46 and 47; Fig. 10 B) or ANT1/2 knock-
out (retransfection with yeast ANT2; references 48 and 49; Fig.
10 A). Thus, genetic manipulations confirm that PTPC
components are rate limiting for the cytotoxic effect of Vpr.
Conclusion. Based on the evidence obtained with cells
(Figs. 1–3, 6 A, and 7), cell-free systems of apoptosis (Fig. 4),
isolated mitochondria (Fig. 5 and Fig. 6 B), purified PTPC
(Fig. 9 A), purified ANT and Bax (Fig. 9 B) and VDAC/
ANT-deficient yeast cells (Fig. 10), it appears that the acute
apoptogenic effect of Vpr involves a direct effect on the
PTPC. This conclusion is corroborated by the interaction
of Vpr with mitochondria (Fig. 7), with proteins from the
PTPC (Fig. 8 and Fig. 9 A), and in particular with the
ANT (Fig. 9 B and surface plasmon resonance data). Addi-
tional mechanisms of Vpr-mediated apoptosis induction have
been suggested, in particular a glucocorticoid-like effect on T
cells (11), plasma membrane permeabilization in neurons (10,
54) (which would, however, involve the NH2 terminus of
Vpr, not the COOH terminus), and cell cycle arrest in pro-
liferating cells (5, 7, 9). Thus, the mechanisms of cell killing by
Vpr may be redundant, at least in some systems. However,
data supporting mitochondrial Vpr effects have been obtained
with different cells (Jurkat, CEM, U937, COS, Rat-1, thy-
mocytes, and human primary PBLs; Figs. 1–3, Fig. 7, and data
not shown), purified mitochondria from distinct organs (lym-
phocytes and liver; Figs. 4 and 5), PTPC from brain (Fig. 9 A),
and a xenogenic yeast system (Fig. 10), underlining the rel-
ative importance of this pathway for Vpr-mediated cell killing.
Vpr and its COOH-terminal moiety have acute cyto-
toxic (2 h) and mitochondriotoxic (5 min) effects at an
ED50 of z1 mM, which is higher than the Vpr serum con-
centration. This might be used as an argument against the
pathophysiological relevance of our studies. Nevertheless,
several considerations have to be taken into account. First,
the mitochondrial receptor for Vpr, the ANT, possesses a
Ka of 7.4 3 1028 M21, meaning that chronic exposure to Vpr
may well have biological effects at lower doses than those
required in short-term assays (in which Vpr must cross sev-
eral diffusion barriers to reach its target). Accordingly, the
Figure 8. Vpr interaction with the PTPC.
(A) Retention of ANT and VDAC by Vpr.
Rat liver mitochondria were incubated with
buffer only (lane 1), NH2-terminally biotiny-
lated Vpr52-96 (lane 2), or nonbiotinylated
Vpr52-96 (lane 3), followed by triton solubi-
lization and purification of proteins interact-
ing with Vpr–biotin–avidin–agarose com-
plex. As a control, the whole mitochondrial
lysate (lane 1) or the avidin-recovered pro-
teins (lanes 2 and 3) were separated by aga-
rose gel electrophoresis, followed by silver
staining or immunodetection of COX (sub-
unit IV; 37 kD), VDAC (32 kD), and ANT (30 kD and dimer of 60 kD). Arrows indicate specific bands of the expected molecular size. (B) Inhibition of
ANT and VDAC binding to Vpr by BA. Rat liver mitochondria were preincubated for 10 min in the absence (Co.) or presence of 50 mM BA, followed by
purification of proteins interacting with biotinylated Vpr52-96 as in A. Then, ANT or VDAC were detected as in A.
Figure 9. Effects of Vpr on the PTPC or PTPC components reconsti-
tuted into liposomes. (A) Effect of Vpr on purified PTPCs. PTPCs were
reconstituted into phosphatidylcholine/cholesterol liposomes (26). These
PTPC liposomes were loaded with DiOC6(3), the retention of which was
measured after treatment with SDS (0.1%), Atr (250 mM), or the indi-
cated Vpr peptides 6 BA (50 mM) or CsA (1mM), as detailed in Materials
and Methods. (B) Effect of Vpr on liposomes containing purified individ-
ual proteins. Phosphatidylcholine/cardiolipin liposomes containing ANT
(from rat heart), Bcl-2 (recombinant), and/or Bax (recombinant) at a mo-
lar ratio of 4:4:1 were treated with SDS (0.1%), Atr (100 mM), or Vpr52-
96 (1 mM), followed by determination of DiOC6(3) release. Data are rep-
resentative of three independent experiments.
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ED50 of Vpr52-96 was found to be z120 nM if cytotoxic
effects were assessed after 24 h (not shown); that is at least
three times lower than the ED50 measured after 2 h (Fig. 6 A).
Second, compartmentalization effects might give rise to lo-
cally elevated concentrations, which suffice to exert biolog-
ical effects in situ. Third, when cooperating with other cyto-
toxic mechanisms, in the context of viral infection, Vpr might
exert its effects at lower doses. Two other HIV-1 proteins,
Tat and PR, may indirectly affect mitochondrial function,
Tat via downregulating mitochondrial superoxide dismutase
(59) and PR by cleaving Bcl-2 (60). This hints at the possibil-
ity that several apoptogenic HIV-1 proteins—Vpr, Tat, and
PR—cooperate at the mitochondrial level, thereby explain-
ing that a fraction of circulating and sessile lymphocytes from
HIV-1 carriers have a low DCm (61, 62).
At the time of this writing, the extent to which Vpr
contributes to HIV-1–induced apoptosis in infected or by-
stander cells is elusive. Early during replication, most if not
all Vpr (which is of viral origin) is found in the preintegra-
tion complex, where it interacts with nucleic acids (which
inhibit the mitochondrial effects of Vpr; Fig. 5) and NCp7,
as well as other proteins (63). Moreover, during the later
stage of the viral life cycle, Vpr synthesized de novo by the
host cell may be sequestered into viral particles before it in-
teracts with its mitochondrial receptor. Alternatively, Vpr
may be released and then act on noninfected bystander
cells. In vitro, HIV-1 strains in which endogenous Env has
been replaced by the general fusogene VSV-G can infect most
mammalian cell types yet induce apoptosis in a largely Vpr-
dependent fashion (9). Thus, at least in some particular set-
tings, Vpr is rate limiting for HIV-1–mediated killing. It is
not known, however, whether this effect is mediated by
Vpr produced by the infected cells or rather involves para-
crine effects. However, the fact that such Vpr-dependent
killing can be obtained in the absence of HIV-1 replication
(64) underlines the possibility that virion-associated Vpr (as
opposed to free soluble Vpr) may well have a cytocidal po-
tential at the beginning of the viral life cycle.
Viruses employ several strategies for the inhibition of ap-
optosis. Thus, viruses may encode homologues of mamma-
lian Bcl-2, FLIP (FLICE-inhibitory protein), inhibitor of
apoptosis proteins (IAPs), or caspase inhibitors to prevent
apoptosis induction during their replication (65). In addi-
tion, many viruses induce apoptosis at the end of the repli-
cation cycle, perhaps as a strategy to hijack the phagocyte
system or to disseminate virions to neighboring cells. To
our knowledge, Vpr from HIV-1 constitutes the first ex-
ample of an apoptogenic viral protein acting on the PTPC.
It is tempting to speculate that similar endogenous peptides
may exist in animal cells and may link proapoptotic signal-
ing to mitochondrial membrane permeabilization. Such
peptides are actually known. They include proapoptotic
members of the Bcl-2/Bax family (24–27), as well as the
proapoptotic peptides from Drosophila melanogaster, Hid,
Reaper, and Grim, all of which have recently been shown to
act on and/or physically interact with mitochondria (66–68).
The NMR structure of the Vpr domain critical for its mi-
tochondrial effects (71HFRIGCRHSRIG82) has been elu-
cidated within Vpr52-96 (40). It is a helical peptide with
three positively charged R residues clustered on one side of
the helix (40). Substitution of these residues abolishes the
apotogenic potential of Vpr (Fig. 1 and Figs. 3–6), under-
lining their importance for Vpr-mediated killing. How-
ever, primary sequence comparisons with Bax, Bak, Bid,
Hid, Reaper, or Grim do not reveal any obvious homology
between these proteins and Vpr. Future studies will unravel
whether motifs resembling the mitochondrio/cytotoxic
domain of Vpr can be identified in such proteins or yet to
be discovered mammalian Vpr analogues.
Irrespective of these theoretical considerations, this re-
port establishes that Vpr is a novel viral effector that di-
rectly targets the PTPC to permeabilize mitochondrial
membranes and induce apoptosis. Based on the premise
that the PTPC exists in all cell types, Vpr thus exploits a
general mechanism to exert its broad cytocidal activity.
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